Info

Oragenics Inc. (Oragenics) is an early-stage biotechnology company aimed at adding value to technologies and products sourced from research at the University of Florida and other academic centers, and from in-licensing from other biotechnology companies. The Company's strategy is to in-license or internally discover products and technologies, to develop products through human proof-of-concept studies (Phase II clinical trials of the United States Food and Drug Administration's (FDA) regulatory process), and to partner with pharmaceutical, biotechnology, or healthcare product firms for advanced clinical development and commercialization. Oragenics possesses seven technologies in research and development, such as MU 1140, Differentially Protected Orthogonal Lanthionine Technology, Vivo Induced Antigen Technology, Change Mediated Antigen Technology, Probiora3, SMaRT Replacement Therapy and LPT3-04.(Source: 10KSB)